Literature DB >> 20420765

Clozapine: a distinct, poorly understood and under-used molecule.

Ridha Joober1, Patricia Boksa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20420765      PMCID： PMC2861131          DOI： 10.1503/jpn.100055

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  42 in total

1.  Do antidepressants really work?

Authors:  Pierre Blier
Journal:  J Psychiatry Neurosci       Date:  2008-03       Impact factor: 6.186

Review 2.  World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.

Authors:  Rajiv Tandon; R H Belmaker; Wagner F Gattaz; Juan J Lopez-Ibor; Ahmed Okasha; Bruce Singh; Dan J Stein; Jean-Pierre Olie; W Wolfang Fleischhacker; Hans-Juergen Moeller
Journal:  Schizophr Res       Date:  2008-02-19       Impact factor: 4.939

Review 3.  Treatment-resistant schizophrenia.

Authors:  Helio Elkis
Journal:  Psychiatr Clin North Am       Date:  2007-09

Review 4.  Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway.

Authors:  R R Girgis; J A Javitch; J A Lieberman
Journal:  Mol Psychiatry       Date:  2008-04-15       Impact factor: 15.992

Review 5.  Who should receive clozapine?

Authors:  S R Marder; T Van Putten
Journal:  Arch Gen Psychiatry       Date:  1988-09

6.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

7.  Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Authors:  S W Lewis; L Davies; P B Jones; T R E Barnes; R M Murray; R Kerwin; D Taylor; K P Hayhurst; A Markwick; H Lloyd; G Dunn
Journal:  Health Technol Assess       Date:  2006-05       Impact factor: 4.014

8.  The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.

Authors:  Henry A Nasrallah
Journal:  J Clin Psychiatry       Date:  2007       Impact factor: 4.384

9.  Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study.

Authors:  Marc De Hert; Christoph U Correll; Dan Cohen
Journal:  Schizophr Res       Date:  2010-01-12       Impact factor: 4.939

10.  The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

Authors:  Troy A Moore; Robert W Buchanan; Peter F Buckley; John A Chiles; Robert R Conley; M Lynn Crismon; Susan M Essock; Molly Finnerty; Stephen R Marder; Del D Miller; Joseph P McEvoy; Delbert G Robinson; Nina R Schooler; Steven P Shon; T Scott Stroup; Alexander L Miller
Journal:  J Clin Psychiatry       Date:  2007-11       Impact factor: 4.384
View more
  17 in total

1.  Which components of specialized early intervention for psychosis do senior providers see as most important?

Authors:  Mark Savill; Angela Sardo; Pooja Patel; Rachel Loewy; Joy Melnikow; Tara Niendam
Journal:  Early Interv Psychiatry       Date:  2018-06-08       Impact factor: 2.732

2.  The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions.

Authors:  Natalia I Brzozowska; Erik J de Tonnerre; Kong M Li; Xiao Suo Wang; Aurelie A Boucher; Paul D Callaghan; Michael Kuligowski; Alex Wong; Jonathon C Arnold
Journal:  Neuropsychopharmacology       Date:  2017-03-08       Impact factor: 7.853

3.  Different pharmacology of N-desmethylclozapine at human and rat M2 and M 4 mAChRs in neocortex.

Authors:  S Gigout; S Wierschke; C Dehnicke; R A Deisz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-01-16       Impact factor: 3.000

4.  Clozapine prescribing in the UK: views and experience of consultant psychiatrists.

Authors:  Tongeji E Tungaraza; Saeed Farooq
Journal:  Ther Adv Psychopharmacol       Date:  2015-04

5.  Community adherence to schizophrenia treatment and safety monitoring guidelines.

Authors:  William R Keller; Bernard A Fischer; Robert McMahon; Walter Meyer; Melissa Blake; Robert W Buchanan
Journal:  J Nerv Ment Dis       Date:  2014-01       Impact factor: 2.254

6.  Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder.

Authors:  Jonne Lintunen; Heidi Taipale; Antti Tanskanen; Ellenor Mittendorfer-Rutz; Jari Tiihonen; Markku Lähteenvuo
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

7.  Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review.

Authors:  Frederike Schirmbeck; Mathias Zink
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

8.  Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors.

Authors:  Frederike Schirmbeck; Mathias Zink
Journal:  Front Pharmacol       Date:  2013-08-09       Impact factor: 5.810

Review 9.  Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action.

Authors:  Tay Kay Yaw; Susan H Fox; Anthony E Lang
Journal:  Mov Disord Clin Pract       Date:  2015-12-30

Review 10.  Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment.

Authors:  Mathias Zink
Journal:  Adv Med       Date:  2014-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.